Dr. Maeve Waldron-Lynch, MD, MRCP (UK) is a medical oncologist/hematologist with over 13 years clinical development experience in the pharmaceutical and biotech industry in both early and late-stage development oncology. Maeve has held roles of increasing responsibility in both large and smaller pharma, including Roche, Novartis and most recently Morphosys. Maeve has successfully led drug development initiatives from clinical trials to regulatory filings, including IND, NDA/BLA submissions, and effective negotiations with global health authorities such as FDA, EMA, PMDA, Health Canada and Swiss Medic.

Maeve completed her undergraduate education at University College Cork, Ireland and is a globally trained hematologist-oncologist, gaining qualifications in oncology from both the Royal College of Physicians of Ireland and Yale Medical School.